Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro‐oesophageal reflux disease – comparator study of esomeprazole, lansoprazole and pantoprazole
Aliment Pharmacol Ther 2010; 32: 200–208 Summary Background Hispanic‐Americans are a rapidly growing population in the United States, yet gastro‐oesophageal reflux disease (GERD) is not well studied in this population. Aim To compare the efficacy of esomeprazole, lansoprazole and pantoprazole in s...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2010-07, Vol.32 (2), p.200-208 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 208 |
|---|---|
| container_issue | 2 |
| container_start_page | 200 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 32 |
| creator | Morgan, D. Pandolfino, J. Katz, P. O. Goldstein, J. L. Barker, P. N. Illueca, M. |
| description | Aliment Pharmacol Ther 2010; 32: 200–208
Summary
Background Hispanic‐Americans are a rapidly growing population in the United States, yet gastro‐oesophageal reflux disease (GERD) is not well studied in this population.
Aim To compare the efficacy of esomeprazole, lansoprazole and pantoprazole in suppressing gastric acid, including the area of the ‘acid pocket,’ in Hispanics with GERD.
Methods In this open‐label, 3‐way crossover study, 83 Hispanics with symptomatic GERD were randomized to 1 of 6 possible treatment sequences of three 5–7‐day dosing periods with esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg daily separated by 10–17‐day washout periods. Intragastric pH was measured for 24 h using dual probes with a distal and proximal (area of the ‘acid pocket’) electrode.
Results Esomeprazole suppressed intragastric acid (pH >4.0) significantly longer over 24 h (primary end point) compared with lansoprazole and pantoprazole (P 4.0) significantly longer over 24 h compared with lansoprazole (P |
| doi_str_mv | 10.1111/j.1365-2036.2010.04335.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733597337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733597337</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4485-b8a4a56bf1d5b0bc2a1fa663d09c3a8d6afdae62121909170aa8211dbc0a56c13</originalsourceid><addsrcrecordid>eNqNUctu1DAUjRCITgu_gLxBbJrBj8STILGoRpQiVYJFWVs3ttN65MTBN1FnWPUTkPgVvqhfgtOZli1e2Pdxzn34ZBlhdMnSeb9ZMiHLnFMhl5ymKC2EKJfbZ9niKfE8W1Au65xXTBxlx4gbSqlcUf4yO-K0KKWgdJH9WXvXOw2ejNGB_0CuAZOlCWhnCE7DEC2iCz1xPblwOEA_J83kRyS3brwhuOuGMXQwpvgDOdzf_QoWw3AD1zYVjrb105YYhxbQkvu730SHboAIY4gEx8nsSGhJYnR2iPAzeHtKPPSpwt4j0BuSGo-PgVfZixY82teH9yT7fv7pan2RX379_GV9dpnroqjKvKmggFI2LTNlQxvNgbUgpTC01gIqI6E1YCVnnNW0ZisKUHHGTKNpomkmTrJ3-7pDDD8mi6PqHGrr03A2TKhW6dPrdK0SstojdQyIaWM1RNdB3ClG1SyZ2qhZGTUro2bJ1INkapuobw5Npqaz5on4qFECvD0AAJNQbYReO_yH43VaoJhn-LjH3Tpvd_89gDr7djVb4i8977mJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733597337</pqid></control><display><type>article</type><title>Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro‐oesophageal reflux disease – comparator study of esomeprazole, lansoprazole and pantoprazole</title><source>MEDLINE</source><source>Wiley Blackwell Single Titles</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Open Access</source><creator>Morgan, D. ; Pandolfino, J. ; Katz, P. O. ; Goldstein, J. L. ; Barker, P. N. ; Illueca, M.</creator><creatorcontrib>Morgan, D. ; Pandolfino, J. ; Katz, P. O. ; Goldstein, J. L. ; Barker, P. N. ; Illueca, M.</creatorcontrib><description>Aliment Pharmacol Ther 2010; 32: 200–208
Summary
Background Hispanic‐Americans are a rapidly growing population in the United States, yet gastro‐oesophageal reflux disease (GERD) is not well studied in this population.
Aim To compare the efficacy of esomeprazole, lansoprazole and pantoprazole in suppressing gastric acid, including the area of the ‘acid pocket,’ in Hispanics with GERD.
Methods In this open‐label, 3‐way crossover study, 83 Hispanics with symptomatic GERD were randomized to 1 of 6 possible treatment sequences of three 5–7‐day dosing periods with esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg daily separated by 10–17‐day washout periods. Intragastric pH was measured for 24 h using dual probes with a distal and proximal (area of the ‘acid pocket’) electrode.
Results Esomeprazole suppressed intragastric acid (pH >4.0) significantly longer over 24 h (primary end point) compared with lansoprazole and pantoprazole (P < 0.0001), and proximal gastric acid (pH >4.0) significantly longer over 24 h compared with lansoprazole (P < 0.05) and pantoprazole (P < 0.0001).
Conclusions Esomeprazole was more effective than lansoprazole and pantoprazole in suppressing gastric acidity at both intragastric distal and proximal (area of the acid pocket) sites in Hispanics with GERD. Future studies are warranted to understand better the role of the acid pocket in GERD (Clinical trial numbers: D9612L00106; ClinicalTrials.gov: NCT00410592).</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2010.04335.x</identifier><identifier>PMID: 20456300</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage ; Adolescent ; Adult ; Aged ; Anti-Ulcer Agents - administration & dosage ; Biological and medical sciences ; Cross-Over Studies ; Digestive system ; Drug Therapy, Combination ; Esomeprazole - administration & dosage ; Esophagus ; Female ; Gastric Acid - secretion ; Gastroenterology. Liver. Pancreas. Abdomen ; Gastroesophageal Reflux - drug therapy ; Hispanic Americans ; Humans ; Lansoprazole ; Male ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Patient Compliance ; Pharmacology. Drug treatments ; Treatment Outcome ; United States ; Young Adult</subject><ispartof>Alimentary pharmacology & therapeutics, 2010-07, Vol.32 (2), p.200-208</ispartof><rights>2010 Blackwell Publishing Ltd</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4485-b8a4a56bf1d5b0bc2a1fa663d09c3a8d6afdae62121909170aa8211dbc0a56c13</citedby><cites>FETCH-LOGICAL-c4485-b8a4a56bf1d5b0bc2a1fa663d09c3a8d6afdae62121909170aa8211dbc0a56c13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2036.2010.04335.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2036.2010.04335.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22912147$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20456300$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morgan, D.</creatorcontrib><creatorcontrib>Pandolfino, J.</creatorcontrib><creatorcontrib>Katz, P. O.</creatorcontrib><creatorcontrib>Goldstein, J. L.</creatorcontrib><creatorcontrib>Barker, P. N.</creatorcontrib><creatorcontrib>Illueca, M.</creatorcontrib><title>Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro‐oesophageal reflux disease – comparator study of esomeprazole, lansoprazole and pantoprazole</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Aliment Pharmacol Ther 2010; 32: 200–208
Summary
Background Hispanic‐Americans are a rapidly growing population in the United States, yet gastro‐oesophageal reflux disease (GERD) is not well studied in this population.
Aim To compare the efficacy of esomeprazole, lansoprazole and pantoprazole in suppressing gastric acid, including the area of the ‘acid pocket,’ in Hispanics with GERD.
Methods In this open‐label, 3‐way crossover study, 83 Hispanics with symptomatic GERD were randomized to 1 of 6 possible treatment sequences of three 5–7‐day dosing periods with esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg daily separated by 10–17‐day washout periods. Intragastric pH was measured for 24 h using dual probes with a distal and proximal (area of the ‘acid pocket’) electrode.
Results Esomeprazole suppressed intragastric acid (pH >4.0) significantly longer over 24 h (primary end point) compared with lansoprazole and pantoprazole (P < 0.0001), and proximal gastric acid (pH >4.0) significantly longer over 24 h compared with lansoprazole (P < 0.05) and pantoprazole (P < 0.0001).
Conclusions Esomeprazole was more effective than lansoprazole and pantoprazole in suppressing gastric acidity at both intragastric distal and proximal (area of the acid pocket) sites in Hispanics with GERD. Future studies are warranted to understand better the role of the acid pocket in GERD (Clinical trial numbers: D9612L00106; ClinicalTrials.gov: NCT00410592).</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Ulcer Agents - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Cross-Over Studies</subject><subject>Digestive system</subject><subject>Drug Therapy, Combination</subject><subject>Esomeprazole - administration & dosage</subject><subject>Esophagus</subject><subject>Female</subject><subject>Gastric Acid - secretion</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gastroesophageal Reflux - drug therapy</subject><subject>Hispanic Americans</subject><subject>Humans</subject><subject>Lansoprazole</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Other diseases. Semiology</subject><subject>Patient Compliance</subject><subject>Pharmacology. Drug treatments</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>Young Adult</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUctu1DAUjRCITgu_gLxBbJrBj8STILGoRpQiVYJFWVs3ttN65MTBN1FnWPUTkPgVvqhfgtOZli1e2Pdxzn34ZBlhdMnSeb9ZMiHLnFMhl5ymKC2EKJfbZ9niKfE8W1Au65xXTBxlx4gbSqlcUf4yO-K0KKWgdJH9WXvXOw2ejNGB_0CuAZOlCWhnCE7DEC2iCz1xPblwOEA_J83kRyS3brwhuOuGMXQwpvgDOdzf_QoWw3AD1zYVjrb105YYhxbQkvu730SHboAIY4gEx8nsSGhJYnR2iPAzeHtKPPSpwt4j0BuSGo-PgVfZixY82teH9yT7fv7pan2RX379_GV9dpnroqjKvKmggFI2LTNlQxvNgbUgpTC01gIqI6E1YCVnnNW0ZisKUHHGTKNpomkmTrJ3-7pDDD8mi6PqHGrr03A2TKhW6dPrdK0SstojdQyIaWM1RNdB3ClG1SyZ2qhZGTUro2bJ1INkapuobw5Npqaz5on4qFECvD0AAJNQbYReO_yH43VaoJhn-LjH3Tpvd_89gDr7djVb4i8977mJ</recordid><startdate>201007</startdate><enddate>201007</enddate><creator>Morgan, D.</creator><creator>Pandolfino, J.</creator><creator>Katz, P. O.</creator><creator>Goldstein, J. L.</creator><creator>Barker, P. N.</creator><creator>Illueca, M.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201007</creationdate><title>Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro‐oesophageal reflux disease – comparator study of esomeprazole, lansoprazole and pantoprazole</title><author>Morgan, D. ; Pandolfino, J. ; Katz, P. O. ; Goldstein, J. L. ; Barker, P. N. ; Illueca, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4485-b8a4a56bf1d5b0bc2a1fa663d09c3a8d6afdae62121909170aa8211dbc0a56c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Ulcer Agents - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Cross-Over Studies</topic><topic>Digestive system</topic><topic>Drug Therapy, Combination</topic><topic>Esomeprazole - administration & dosage</topic><topic>Esophagus</topic><topic>Female</topic><topic>Gastric Acid - secretion</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gastroesophageal Reflux - drug therapy</topic><topic>Hispanic Americans</topic><topic>Humans</topic><topic>Lansoprazole</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Other diseases. Semiology</topic><topic>Patient Compliance</topic><topic>Pharmacology. Drug treatments</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morgan, D.</creatorcontrib><creatorcontrib>Pandolfino, J.</creatorcontrib><creatorcontrib>Katz, P. O.</creatorcontrib><creatorcontrib>Goldstein, J. L.</creatorcontrib><creatorcontrib>Barker, P. N.</creatorcontrib><creatorcontrib>Illueca, M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morgan, D.</au><au>Pandolfino, J.</au><au>Katz, P. O.</au><au>Goldstein, J. L.</au><au>Barker, P. N.</au><au>Illueca, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro‐oesophageal reflux disease – comparator study of esomeprazole, lansoprazole and pantoprazole</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2010-07</date><risdate>2010</risdate><volume>32</volume><issue>2</issue><spage>200</spage><epage>208</epage><pages>200-208</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Aliment Pharmacol Ther 2010; 32: 200–208
Summary
Background Hispanic‐Americans are a rapidly growing population in the United States, yet gastro‐oesophageal reflux disease (GERD) is not well studied in this population.
Aim To compare the efficacy of esomeprazole, lansoprazole and pantoprazole in suppressing gastric acid, including the area of the ‘acid pocket,’ in Hispanics with GERD.
Methods In this open‐label, 3‐way crossover study, 83 Hispanics with symptomatic GERD were randomized to 1 of 6 possible treatment sequences of three 5–7‐day dosing periods with esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg daily separated by 10–17‐day washout periods. Intragastric pH was measured for 24 h using dual probes with a distal and proximal (area of the ‘acid pocket’) electrode.
Results Esomeprazole suppressed intragastric acid (pH >4.0) significantly longer over 24 h (primary end point) compared with lansoprazole and pantoprazole (P < 0.0001), and proximal gastric acid (pH >4.0) significantly longer over 24 h compared with lansoprazole (P < 0.05) and pantoprazole (P < 0.0001).
Conclusions Esomeprazole was more effective than lansoprazole and pantoprazole in suppressing gastric acidity at both intragastric distal and proximal (area of the acid pocket) sites in Hispanics with GERD. Future studies are warranted to understand better the role of the acid pocket in GERD (Clinical trial numbers: D9612L00106; ClinicalTrials.gov: NCT00410592).</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20456300</pmid><doi>10.1111/j.1365-2036.2010.04335.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2010-07, Vol.32 (2), p.200-208 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733597337 |
| source | MEDLINE; Wiley Blackwell Single Titles; EZB-FREE-00999 freely available EZB journals; Wiley Open Access |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage Adolescent Adult Aged Anti-Ulcer Agents - administration & dosage Biological and medical sciences Cross-Over Studies Digestive system Drug Therapy, Combination Esomeprazole - administration & dosage Esophagus Female Gastric Acid - secretion Gastroenterology. Liver. Pancreas. Abdomen Gastroesophageal Reflux - drug therapy Hispanic Americans Humans Lansoprazole Male Medical sciences Middle Aged Other diseases. Semiology Patient Compliance Pharmacology. Drug treatments Treatment Outcome United States Young Adult |
| title | Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro‐oesophageal reflux disease – comparator study of esomeprazole, lansoprazole and pantoprazole |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A40%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20trial:%20gastric%20acid%20suppression%20in%20Hispanic%20adults%20with%20symptomatic%20gastro%E2%80%90oesophageal%20reflux%20disease%20%E2%80%93%20comparator%20study%20of%20esomeprazole,%20lansoprazole%20and%20pantoprazole&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Morgan,%20D.&rft.date=2010-07&rft.volume=32&rft.issue=2&rft.spage=200&rft.epage=208&rft.pages=200-208&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2010.04335.x&rft_dat=%3Cproquest_cross%3E733597337%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733597337&rft_id=info:pmid/20456300&rfr_iscdi=true |